present
review
attempt
summar
huge
volum
data
wide
studi
class
small
molecul
use
modern
organ
medicin
chemistri
manuscript
cover
approach
synthesi
deriv
modif
posit
basic
core
synthesi
target
compound
onepot
multistag
reaction
transform
relat
heterocycl
promin
pharmacolog
profil
deriv
differ
subtyp
belong
hit
leadcompound
drugcandid
drug
well
studi
target
discuss
current
target
compound
especi
assign
frequent
hitter
panassay
interfer
compound
pain
within
highthroughput
screen
campaign
nevertheless
crucial
impact
presenc
natur
substitu
name
pharmacolog
effect
confirm
numer
list
find
origin
articl
main
direct
activ
optim
shown
complic
fragment
posit
ii
introduct
substitu
posit
especi
fragment
carboxyl
group
deriv
iii
anneal
complex
heterocycl
system
iv
combin
pharmacolog
attract
fragment
within
hybrid
pharmacophor
approach
moreov
util
synthesi
complex
compound
potent
pharmacolog
applic
describ
chemic
transform
cover
mainli
reaction
involv
exocycl
doubl
bond
posit
main
core
correspond
abovement
direct
modif
relat
heterocycl
base
compound
extens
explor
sourc
antiinflammatori
antitumor
antimicrobi
antidiabet
antibacteri
agent
find
medicin
chemistri
pharmacolog
significantli
increas
sinc
reflect
rapid
growth
number
scientif
paper
numer
review
patent
cover
variou
deriv
paper
dedic
select
subtyp
name
imino
exocycl
doubl
bond
c
posit
etc
prove
belong
privileg
scaffold
modern
medicin
chemistri
combin
sever
reaction
center
structur
deriv
make
effect
tool
ration
divers
orient
synthesi
privileg
substructurebas
divers
orient
synthesi
new
leadcompound
creation
major
achiev
field
relat
rhodanin
aryl
substitut
imino
substitut
subtyp
sourc
antimicrobi
antidiabet
antiinflammatori
anticanc
leadcompound
drugcandid
larg
due
investig
introduct
medic
practic
antidiabet
drug
glitazon
peroxisom
proliferatoractiv
receptorg
ppar
agonist
eg
rosiglitazon
troglitazon
pioglitazon
etc
aldos
reductas
inhibitor
epalrestat
simplic
synthesi
abovement
compound
less
attent
paid
imino
deriv
isorhodanin
thiorhodanin
especi
imino
deriv
despit
forego
among
subtyp
substitut
thiazolidinon
name
deriv
special
interest
context
chemic
featur
pharmacolog
profil
manuscript
tri
present
power
pharmacolog
chemic
potenti
pursu
goal
devid
thiazolidinon
accord
natur
substitu
eg
deriv
rhodanin
etc
fig
argument
favour
follow
larg
number
review
devot
select
thiazolidinon
subtyp
ii
gener
differ
thiazolidinon
core
character
pharmacolog
profil
see
well
similar
synthet
protocol
method
use
synthesi
deriv
depend
undoubtedli
natur
thiazolidinon
subtyp
well
repres
numer
review
origin
articl
see
present
retrosynthet
approach
fig
show
wide
rang
synthet
rout
thiazolidin
ring
format
base
variou
condens
reaction
success
employ
synthesi
approach
also
specul
attract
synthesi
posit
isom
mention
structur
rare
repres
promin
refer
protocol
synthesi
cyclocondens
reactant
bear
fragment
ahalocarbonyl
compound
case
mention
protocol
lead
format
howev
protocol
synthesi
deriv
often
similar
divid
next
group
modif
posit
basic
core
ii
synthesi
target
compound
onepot
multistag
reaction
simultan
format
core
heterocycl
exocycl
doubl
bond
iii
transform
thiazolidin
deriv
relat
heterocycl
recycl
reaction
knoevenagel
condens
one
promin
refer
protocol
synthesi
knoevenagel
condens
thiazolidinon
core
oxocompound
scheme
methylen
carbon
atom
possess
nucleophil
activ
attack
electrophil
center
afford
target
enederiv
differ
aldehyd
keton
heterocycl
eg
isatin
anhydrid
phthalic
acid
etc
use
oxo
compound
acet
acid
anhydrid
sodium
acet
ethanol
ammonium
acet
piperidin
toluen
ammonia
acet
isopropanol
potassium
tertbutyl
toluen
lprolin
dimethylformamid
sodium
acet
ethanol
monoethanolamin
well
solid
carrier
phasetransf
catalyst
etc
wide
use
medium
catalyst
reaction
reaction
perform
also
describ
medium
aldehyd
keton
without
solvent
addit
base
green
chemistri
approach
moreov
perform
condens
aqueou
solut
usag
atyp
agent
well
ionic
liquid
solubl
polymersupport
synthesi
also
investig
microwav
assist
organ
synthesi
approach
also
success
employ
util
aromat
aldehyd
lead
maxim
yield
target
compound
unlik
aliphat
aldehyd
especi
keton
reactiv
differ
also
depend
main
core
substitu
rhodanin
etc
rhodanin
react
easier
imino
etc
character
lower
reactiv
level
aldehyd
util
prefer
mostli
one
product
report
z
geometri
base
nmr
studi
regardless
thiazolidinon
subtyp
knoevenagel
condens
keton
gener
lead
mixtur
zand
eisom
use
dicarbonyl
compound
reaction
lead
format
unfus
heterocycl
two
thiazolidinon
fragment
molecul
despit
simplic
condens
format
product
report
also
instanc
thiopyrano
thiazol
obtain
highli
reactiv
thi
keton
ethanol
presenc
monoethanolamin
condens
formaldehyd
water
triethylamin
lead
format
uncatalyz
reaction
water
bondform
report
thiazolidinedioneisatin
conjug
synthet
protocol
format
product
found
thermodynam
control
heat
lead
dehydr
doubl
bound
format
posit
thiozolidinon
core
scheme
reaction
pseudothiohydantoin
isatin
molar
ratio
carri
absolut
ethanol
reflux
afford
target
also
spiroisatin
conjug
base
knoevenagel
condens
effici
method
synthesi
use
triethylorthoform
describ
latter
easili
convert
knoevenagel
condens
often
may
stage
tandem
andor
domino
reaction
whilst
correspond
appear
intermedi
synthesi
fuse
thiazolidinonebas
heterocycl
see
bellow
simpl
molecul
thiazolidinon
subtyp
exampl
effici
approach
obtain
via
sulfurnitrogen
displac
base
develop
multicompon
reaction
involv
knoevenagel
condens
onepot
reaction
isatin
deriv
rhodanin
secondari
amin
magnesium
oxid
nanoparticl
use
heterogen
catalyst
water
medium
rt
effici
green
approach
prepar
novel
isatinthiazolidinon
base
conjug
scheme
develop
fast
effici
protocol
gener
scheme
sequenti
onepot
twostep
process
combin
knoevenagel
condens
alkyl
reaction
microwav
assist
condit
type
condens
activ
methylen
group
condens
dimethylformamidedimethylacet
dmfdma
dioxan
yield
correspond
enamin
moreov
methylen
group
coupl
aryldiazonium
salt
etohnaoh
form
correspond
arylhydrazon
scheme
similar
case
zisom
form
confirm
xray
data
isoster
also
prepar
singl
step
simultan
treatment
dmfdma
lawesson
reagent
toluen
medium
action
dmfpocl
relat
enamin
deriv
pyrolo
synthes
scheme
activ
methylen
group
underw
nucleophil
addit
reaction
doubl
bond
variou
aryliden
malononitril
via
michael
type
addit
reaction
ethanol
medium
presenc
piperidin
give
instanc
reaction
andor
provid
appropri
format
instead
expect
fuse
heterocycl
propos
reaction
proceed
via
nucleophil
addit
bcarbon
activ
doubl
bond
nitril
form
adduct
follow
elimin
malononitril
ethylcyanoacet
step
propos
mechan
dihydrothiophen
deriv
format
via
fourcompon
reaction
aldehyd
malonitril
piperidin
presenc
bu
noh
basic
ionic
liquid
medium
via
triethylaminecatalyz
domino
reaction
isothiocyan
base
synthesi
reaction
arylisothiocyan
dmf
presenc
koh
provid
appropri
thioamid
may
treat
effect
build
block
synthesi
polyfunct
compound
latter
react
hydrazonoyl
halid
afford
new
deriv
scheme
one
effici
method
synthesi
reaction
eg
acid
anilidevinyl
compound
hemicyanin
format
dimethinemerocyanin
cyanin
dye
scheme
merocyanin
dye
exampl
polycycl
heterocycl
deriv
synthesi
involv
activ
methylen
group
thiazolidinon
core
methyl
thioxogroup
posit
acid
scheme
heterocycl
sme
salt
scheme
rhodanin
deriv
acid
via
action
thionyl
chlorid
expos
dimeris
posit
yield
appropri
acyl
chlorid
use
modif
scheme
reaction
aryl
rhodanin
bi
trimethylsilyl
formamid
also
led
dimeris
format
bi
methinoxyn
reaction
halogen
led
simpl
scheme
effect
reagent
synthet
transform
thu
base
ethyl
ester
acid
origin
method
deriv
synthesi
propos
anoth
effici
method
synthesi
especi
case
compound
contain
carboxyl
carbonyl
group
substitu
dehydrobromin
reaction
scheme
rhodanin
react
bromin
acet
acid
form
mixtur
eand
zstereoisom
describ
ester
acid
attract
build
block
variou
subtyp
synthesi
thiocarbam
doubl
bond
result
spontan
heterocyl
intermedi
oxid
presenc
triethylamin
scheme
protocol
present
rather
simpl
explor
twoor
threestep
procedur
consid
current
trend
organicmedicin
chemistri
differ
onepot
multicompon
method
propos
synthesi
scheme
illustr
exampl
onepot
method
base
cyclocondens
substitut
thioureasthiosemicarbazid
halogencarboxyl
acid
follow
knoevenagel
condens
design
laboratori
wide
use
wet
chemistri
condit
well
microwav
irradi
green
reaction
media
approach
success
employ
synthesi
fuse
heterocycl
bear
moieti
eg
thioamid
bunsatur
acid
reaction
acethylenedicarboxyl
acid
propion
acid
ester
aceton
medium
also
yield
thiazolidinon
well
thiazanon
threecompon
reaction
amin
dialkyl
acetylenedicarboxyl
carbon
disulfid
yield
relat
rhodanin
deriv
scheme
isocyan
util
instead
carbon
sulfid
condit
led
maleimid
deriv
format
explor
achlorob
galkeno
ester
type
multicompon
reaction
led
format
z
uncommon
compound
arylpropiol
effici
build
block
construct
scheme
reaction
latter
bifunct
sulfur
pronucleophil
phosphinecatalyz
tandem
process
includ
umpolung
addit
intramolecular
cycliz
similarli
rhodanin
deriv
synthes
dithiocarbam
phosphin
catalyz
reaction
scheme
reaction
trisubstitut
thiourea
dimethylacetylenedicarboxyl
dmda
methanol
medium
also
lead
adduct
scheme
similarli
pseudothiohydantoin
one
deriv
easili
obtain
propenoylthiourea
oxid
eg
bromin
action
scheme
novel
bunsatur
ester
synthes
multicompon
reaction
aldehyd
thiosemicarbazid
dimethylacetylenedicarboxyl
ethanol
medium
interestingli
reaction
nt
depend
presenc
electronwithdraw
electron
donat
group
involv
thiosemicarbazon
format
follow
michael
addit
sulfur
atom
tripl
bond
sequenti
cycliz
scheme
epoxi
acid
cisand
transepoxysuccin
methylcisepoxysuccin
acid
constitut
anoth
equival
dielectrophil
synthon
c
cyclocondens
reaction
thiourea
obtain
pseudothiohydantoin
scheme
fast
high
yield
protocol
gener
substitut
sequenti
onepot
twostep
process
combin
holmberg
method
knoevenagel
condens
microwav
assist
condit
develop
scheme
import
synthet
rout
reaction
amercaptocarboxyl
acid
deriv
ethylcyanoacet
cyanoacetamid
malonodinitril
etc
well
cyclocondens
oxonitril
cyanoguanidin
acid
deriv
scheme
obtain
expos
regioselect
bromin
dehydrogen
form
deriv
conveni
method
synthesi
onepot
threecompon
reaction
primari
amin
oxocompound
thiolic
agent
use
variou
reaction
condit
extend
heat
dehydr
agent
use
acyl
agent
microwaveassist
organ
synthesi
base
retrosynthet
approach
synthesi
propos
scheme
acid
obtain
use
thiolic
agent
prepar
one
onepot
reaction
base
condens
ethylthiocyanoacet
arylidenehydrazin
hydrazin
hydrat
glacial
acet
acid
also
led
format
scheme
similarli
synthesi
sequenti
threecompon
reaction
involv
primari
amin
isothiocyan
propos
effici
method
initi
regioselect
smichael
addit
thiourea
intermedi
result
coupl
amin
isothiocyan
electrophil
center
next
step
intramolecular
attack
nh
obtain
isothiourea
deriv
ester
group
hydrazon
chain
loss
alcohol
molecul
hydrolyt
cleavag
hydrazid
moieti
afford
new
thiazolidinon
transform
relat
heterocycl
aim
form
often
explor
synthesi
due
simplic
method
describ
howev
reaction
monosubstitut
urea
rearrang
occur
yield
start
obtain
reaction
formyl
scheme
pharmacolog
attract
agent
among
compound
exactli
exocycl
doubl
bond
reflect
crucial
impact
presencenatur
name
substitu
thiazolidon
ring
pharmacolog
effect
time
ar
yliden
fragment
conjug
carbonyl
group
thiazolidinon
core
make
compound
electrophil
potenti
reactiv
due
possibl
michael
addit
exocycl
doubl
bond
nucleophil
protein
residu
moreov
react
glutathion
free
thiol
within
cell
sheme
properti
character
mainli
rhodanin
deriv
frequent
hitter
pan
assay
interfer
compound
pain
thought
useless
modern
drug
discoveri
process
possiblepredict
insuffici
select
along
structur
featur
offer
high
probabl
polar
interact
hydrogen
bond
format
caus
promiscu
behavior
concentr
within
screen
rang
statement
regard
gener
knock
criterion
exclud
screen
hit
develop
suggest
special
criteria
target
affin
select
must
appli
class
compound
except
potenti
valuabl
biomolecular
bind
properti
consequ
exploit
use
way
interpret
frequent
hitter
often
confirm
experiment
studi
larg
number
leadcompound
belong
posit
perspect
may
also
associ
polypharmacolog
approach
drug
discoveri
affin
toward
variou
target
regard
advantag
moreov
mention
compound
exampl
privileg
scaffold
treat
druglik
molecul
provid
baselin
affin
whole
protein
famili
addit
better
result
drug
design
expect
respons
evok
multipoint
intervent
one
mechan
toward
differ
target
follow
concept
multitarget
drug
also
known
dual
symbiot
drug
exploit
divers
allow
achiev
desir
combin
molecular
fragment
mani
report
describ
presenc
heterocycl
moieti
thiazol
pyrazol
flavon
chromon
furan
etc
posit
thiazolidinon
core
even
consid
fragment
molecul
effect
compar
molecul
includ
simpl
aryl
group
see
spirit
lack
strict
specif
ligand
bind
possibl
influenc
compound
metabolit
pathway
activ
discuss
concept
one
argument
favour
search
nonspecif
biolog
activ
compound
furthermor
mani
compound
possess
differ
type
activ
appar
due
action
toward
differ
metabol
pathway
target
involv
biolog
target
metabol
pathway
variou
patholog
thu
mani
author
consid
thiazolidinon
relat
scaffold
regard
problemat
promiscu
binder
per
se
intermolecular
interact
profil
scaffold
make
prone
bind
larg
number
target
weak
moder
affin
may
observ
moder
affin
eg
screen
campaign
overinterpret
past
compound
easili
put
forward
lead
compound
develop
context
worth
mention
exactli
michael
acceptor
among
effect
activ
modif
open
new
perspect
treatment
inflamm
cancer
etc
moreov
michael
acceptor
includ
belong
new
class
highli
specif
potent
inhibitor
mitochondri
pyruv
carrier
addit
emphas
possibl
michael
acceptor
calcul
predict
base
molecular
structur
use
silico
studi
often
confirm
experiment
condit
close
physiolog
besid
mention
earlier
wide
use
design
complex
heterocycl
system
within
hybrid
pharmacophor
approach
signific
biolog
potenc
compound
bear
fragment
combin
exampl
heterocycl
scaffold
discov
satisfactori
toxicolog
paramet
compound
may
addit
argument
favour
develop
studi
next
chapter
repres
promin
pharmacolog
profil
differ
subtyp
belong
hit
leadcompound
drugcandid
drug
two
main
direct
studi
biolog
activ
deriv
present
identif
number
compound
possess
type
biolog
activ
screen
procedur
without
molecular
target
identif
design
highaffin
ligand
establish
molecular
target
instanc
lot
thiazolidinon
prove
ligand
biolog
target
present
protein
data
bank
wwwrscborg
moreov
sever
type
activ
often
describ
compound
clearli
follow
said
larg
number
public
dedic
silico
studi
particularli
deriv
paper
focu
data
wide
outlin
review
paper
wide
rang
establish
pharmacolog
activ
allow
describ
type
given
manuscript
therebi
focus
studi
describ
type
activ
antimicrobi
antitumor
etc
besid
compound
bear
fuse
fragment
eg
thiazolothiopyran
thiazolopyridin
etc
beyond
scope
paper
one
earliest
direct
biolog
assay
lie
field
antibacteri
antifung
activ
search
appar
structur
similar
penicillin
antibiot
stimulu
studi
type
activ
though
recent
discov
manifest
antibacteri
effect
alway
relat
penicillin
mode
action
usual
tendenc
move
detect
antimicrobi
activ
within
screen
program
identif
design
high
affin
ligand
valid
molecular
target
regardless
natur
basic
core
rhodanin
etc
modif
complic
yliden
fragment
benefit
realiz
type
activ
role
halogenaryliden
moieti
stress
especi
acid
repres
group
compound
signific
antimicrobi
activ
gramposit
gramneg
microorgan
molecular
mode
action
associ
inhibit
last
two
stage
peptidoglycan
cell
wall
biosynthesi
attract
target
new
antimicrobi
design
mainli
penicillinbind
protein
famili
transferas
e
udpmurnacpeptidas
activ
dehydrogenas
compound
relat
structur
cross
bacteri
cell
wall
lead
identif
catecholrhodanin
core
privileg
scaffold
design
dehydrogenas
inhibitor
iii
peptid
deformylas
leadcompound
ic
mm
mm
correspondli
etc
scheme
seri
acid
deriv
scheme
describ
inhibitor
fungal
protein
mannosyl
transferas
micromolar
level
design
compound
also
base
complic
moieti
highthroughput
screen
acid
prove
anthrax
lethal
factor
one
major
virul
factor
inhibitor
ic
antimicrobi
activ
compound
determin
inhibit
penicillinbind
protein
famili
group
transferas
includ
udpmurnacpeptidas
subtyp
character
distinct
transglycosylas
activ
atpdepend
amino
acid
ligas
murc
murd
mure
murf
murg
illustr
exampl
antibacteri
agent
design
instanc
effici
inhibitor
murc
udpnacetylmuramatelalanin
ligas
e
murg
emphas
rhodanin
core
treat
novel
phosphat
mimic
scheme
structur
similar
compound
inhibitor
dtdprhamnos
synthesi
especi
import
antimycobacteri
agent
search
mycobacteri
cell
wall
uniqu
contain
amycolylarabinogalactan
layer
bound
peptidoglycan
layer
via
rhamnoseeglcnac
sugar
linker
dtdprhamnos
vetreat
precursor
deriv
competit
inhibitor
recombin
bacteri
arylaminenacetyltransferas
nat
design
base
structur
modif
n
methyl
substitut
weak
inhibitor
nat
scheme
one
pathogenet
process
proand
eukaryot
mechan
associ
galactofuranosebas
conjug
involv
udpgalactopyranos
mutas
ugm
inhibit
process
lead
inhibit
microbi
growth
reduct
virul
especi
mycobacterium
tuberculosi
improv
antimicrobialantimycobacteri
activ
ugm
inhibitor
high
inhibit
activ
enzym
also
discov
acid
deriv
scheme
imino
wide
investig
antimicrobi
agent
eg
compound
identifi
inhibitor
type
iii
secret
system
gramneg
bacteria
pseudomona
aeruginosa
shown
reduct
elastas
secret
presenc
type
ii
secret
system
well
conserv
among
gram
neg
bacteria
key
virul
factor
p
aeruginosa
structur
optim
aim
increas
solubl
led
compound
possess
superior
activ
mm
typhimurium
secret
assay
posit
establish
permiss
optim
direct
scheme
find
suitabl
deriv
e
modif
provid
fold
increas
antimicrobi
activ
relat
detect
high
activ
inhibitor
phosphatedepend
oacetylsulfhydrylas
catalyz
format
lcystein
oacetylserin
hydrogensulfid
cystein
biosynthet
pathway
one
essenti
pathway
microbi
pathogen
provid
potenti
target
develop
novel
antibacteri
compound
scheme
row
bear
nitro
group
small
heterocycl
fragment
thiazol
benzthiazol
isatin
pyrazol
furan
thiophen
scheme
posit
show
suffici
antimicrobi
activ
level
nitro
deriv
character
high
renal
excret
use
design
potenti
diuret
result
qsar
studi
reveal
compound
less
number
atom
less
number
substitu
like
activ
counterpart
higher
molecular
weight
simpl
aryliden
analog
propos
novel
class
blactamas
inhibitor
posses
select
class
c
blactamas
nonblactam
ic
mm
class
c
enzym
simpl
discov
effect
inhibitor
quorum
sens
mechan
bacteria
regul
gene
express
respons
popul
densiti
includ
regul
product
virul
factor
etc
virul
target
repres
emerg
concept
antibacteri
therapi
exampl
compound
inhibit
virul
function
hybrid
may
provid
critic
step
toward
valid
strategi
develop
novel
therapeut
scheme
compound
bulki
aromat
substitu
posit
tryptophan
residu
posit
rhodanin
ring
activ
inha
carrier
protein
reductas
micromolar
ic
vitro
antiamoeb
activ
evalu
imss
strain
entamoeba
histolytica
exhibit
promis
activ
ic
mm
lower
metronidazol
ic
mm
low
toxic
level
scheme
sever
azafus
rhodacyanin
found
perspect
agent
test
variou
heterocycl
ring
antimalari
activ
among
test
compound
show
excel
inhibitori
activ
ic
nm
anoth
compound
quinolin
ring
two
rhodanin
moieti
show
suppress
parasitemia
mgkgday
acid
belong
rhodacyanin
dye
character
distinct
antimalari
activ
signific
anticanc
activ
mention
class
compound
emphas
context
see
scheme
vitro
structureeact
relationship
investig
show
rhodacyanin
possess
high
antimalari
activ
ec
nm
signific
select
toxic
well
seri
analog
screen
compound
antimalari
activ
use
agglom
structur
cluster
techniqu
allow
identifi
start
point
lead
optim
includ
imino
thiazolidinon
deriv
posit
isom
mention
deriv
e
compound
also
describ
compound
librari
potenti
antimalari
lead
scheme
area
antiprotozo
agent
search
design
antitrypanoson
agent
base
thiazolidinon
scaffold
special
interest
compound
show
highest
antiprolif
activ
comparison
analog
screen
trypanosoma
cruzi
epimastigot
inact
toward
cruzipain
scheme
obtain
virtual
screen
chemic
structur
databas
cruzipain
inhibit
enzym
micromolar
concentr
acid
deriv
report
possess
inhibitori
activ
trypanosoma
brucei
dolicholphosph
mannos
synthas
glycosylphosphatidylinositol
anchor
synthesi
well
vitro
trypanocid
activ
blood
stream
form
noncytotox
hela
cell
dolicholphosphatemannos
synthas
mannosyl
transferas
critic
involv
glycoconjug
biosynthesi
brucei
vsg
dimmer
cover
parasit
cellsurfac
link
trypanosom
plasma
membran
via
glycosyl
phosphatidylinositol
anchor
biosynthesi
essenti
viabil
blood
stream
form
brucei
analog
show
best
trypanocid
activ
ed
mm
scheme
simpl
hydroxyphenylmethyliden
describ
novel
inhibitor
leishmania
pteridin
reductas
thiazolidinon
ring
treat
bioisoster
replac
pteridinepurin
ring
one
discuss
mode
action
thiazolidinon
base
compound
dnabind
process
studi
deriv
design
potent
molecul
bound
dna
minor
groov
involv
van
der
waal
hbond
hydrophob
interact
scheme
search
new
antidiabet
agent
among
one
studi
field
result
introduct
new
class
antidiabet
drug
e
glitazon
mechan
action
associ
activ
pparg
peroxisom
prolifer
activ
receptor
scheme
howev
deriv
includ
analog
glitazon
lesser
extent
activ
ppar
introduct
carboxyl
acid
residu
posit
lead
decreas
hepatotox
glitazon
well
unsatur
structur
analog
acid
compound
relat
deriv
report
low
activ
ppar
high
antidiabet
activ
vivo
confirm
sucroseload
model
indic
mode
antihyperglycem
action
treat
glitason
bioisost
deriv
possess
antihyperglycem
activ
oppos
troglitazon
experiment
condit
evalu
vitro
insulin
releas
activ
cell
latter
decreas
level
hyperglycemia
scheme
structur
relat
bulki
fragment
treat
potent
euglycem
hypolipidem
agent
well
simpl
analog
alloxaninduc
hyperglycemia
vivo
mice
model
scheme
howev
studi
pparrel
action
continu
virtual
screen
tool
includ
squirrel
sophist
quantif
interact
relationship
procedur
allow
detect
set
potenti
ppar
ligand
compound
includ
show
ppara
pparg
agonist
activ
leadcompound
possess
nanolevel
activ
ec
ppara
mm
scheme
new
seri
pparg
agonist
known
bcarboxyethyl
rhodanin
deriv
identifi
base
ligandcentr
receptorcentr
approach
vitro
assay
confirm
nanomolar
bind
affin
cellbas
transactiv
assay
similar
pparg
agonist
activ
known
pparg
drug
pioglitazon
shown
base
comfa
model
dock
data
discov
electrostat
interact
carboxyethyl
group
rhodanin
core
import
bind
pocket
pparg
rhodanin
heterocycl
play
differ
role
thiazolidin
group
rosiglitazon
current
investig
pparg
antagonist
also
great
interest
treatment
diabet
obes
includ
studi
investig
mechan
antidiabet
mode
action
inhibit
aldos
reductas
ar
aldos
reductas
limit
enzym
polyolsorbitol
pathway
glucos
oxid
excess
activ
lead
accumul
glucitol
develop
diabet
complic
acid
high
affin
inhibitor
aldos
reductas
illustr
exampl
mention
compound
row
epalrestat
e
z
e
acid
optim
compound
structur
mainli
associ
fragment
modif
studi
epalrestat
analog
reveal
zisom
possess
higher
activ
level
great
interest
deriv
ar
inhibitor
sinc
view
hydantoin
rhodanin
bioisoster
potenti
free
hypersensit
reaction
link
presenc
hydantoin
system
fact
date
sever
patent
dual
activ
antihyperglycaem
inhibitori
agent
find
suggest
activ
compound
might
correl
inhibitori
abil
prevent
stimul
pkc
mapk
subsequ
activ
nfkb
play
pivot
role
mediat
oxid
stressinduc
inflamm
implic
develop
variou
inflammatori
patholog
see
enzym
catalyz
reduct
lipid
peroxidationderiv
aldehyd
thu
produc
metabolit
transduc
inflammatori
signal
mean
activ
protein
kinas
pkc
mapk
turn
activ
nfkb
respons
transcript
mani
proinflammatori
gene
antidiabet
activ
target
compound
often
relat
inhibit
ptp
protein
tyrosin
phosphatas
intracellular
ptp
key
neg
regul
insulin
signal
pathway
well
lmwptp
low
molecular
weight
protein
tyrosin
phosphatas
possibl
mode
action
may
regard
attract
approach
design
new
therapeut
agent
treatment
type
diabet
mellitu
obes
therefor
state
associ
complex
metabol
disord
known
metabol
syndrom
methylbenzo
acid
indic
inhibitor
ptp
lmwptp
scheme
one
direct
studi
exampl
util
phosphotyrosinemimet
identifi
effect
low
molecular
weight
nonphosphoru
inhibitor
ptp
pmethylbenzo
acid
residu
posit
scaffold
act
monoanion
ptyrmimet
group
replic
interact
ptyr
catalyt
site
enzym
studi
author
also
note
import
fragment
alkylatedacyl
phenol
group
methoxi
group
desir
inhibitori
effect
e
compound
relat
pioglitazon
pparagonist
also
possess
antidiabet
activ
vivo
data
reveal
abil
reduc
blood
glucos
triglycerid
level
reduc
obes
screen
studi
allow
identifi
confirm
activ
deriv
inhibitor
glycogen
synthas
turn
emerg
key
therapeut
target
type
diabet
also
alzheimersdiseas
cancer
chronic
inflamm
simpl
deriv
present
new
class
aglucosidas
inhibitor
scheme
aglucosidas
adglucosideglucohydrolas
membran
bound
exoact
enzym
respons
catalyz
final
step
digest
process
carbohydr
metabol
aglucosidas
enzym
hydrolyz
oand
sglycosyl
residu
involv
biosynthesi
process
oligosaccharid
chain
nlink
glycoprotein
endoplasm
reticulum
carri
dioxin
fragment
prove
glycogen
phosphorylas
inhibitor
scheme
glycogen
phosphorylas
key
enzym
regul
blood
sugar
level
catalyz
format
glycogen
may
relev
control
blood
glucos
concentr
type
diabet
search
new
anticanc
agent
dynam
develop
area
medicin
chemistri
lot
paper
patent
devot
search
effici
anticanc
agent
among
includ
deriv
select
row
patent
see
esi
research
area
could
divid
next
group
vitro
screen
highli
activeselect
hitcompound
optim
mainli
unknown
mode
action
includ
intern
program
mainli
development
therapeut
program
nci
nih
http
dtp
cancergov
ii
design
highaffin
ligand
valid
anticanc
biotarget
iii
creation
hybrid
molecul
combin
sever
pharmacolog
attract
scaffold
iv
search
antitumor
agent
among
compound
known
biolog
activ
antiinflammatori
antidiabet
antior
prooxid
etc
known
possess
good
activ
differ
type
cancer
includ
rel
simpl
deriv
well
complex
hybridsconjug
bear
nonfus
fragment
mention
compound
nt
belong
classic
anticanc
agent
type
despit
divers
search
antileukem
agent
one
promis
direct
found
tendenc
maximum
sensit
leukemia
cell
line
variou
subtyp
thiazolidinon
crucial
role
ylid
ene
fragment
also
confirm
complic
enefrag
consid
benefit
antileukem
effect
compound
less
document
comparis
cancer
type
among
acid
deriv
amid
scheme
anticanc
activ
identifi
includ
sampl
possess
strong
antileukem
activ
sar
studi
reveal
anticanc
activ
significantli
decreas
disappear
transform
relat
isoster
compound
replac
aryliden
moieti
fragment
case
compound
base
relat
heterocycl
core
eg
moreov
novel
acid
amid
bear
furan
moieti
exhibit
signific
cytotox
induct
apoptosi
human
leukemia
cell
among
imino
set
activ
compound
micromolar
ic
level
detect
log
gi
base
obtain
result
compound
bulki
fragment
benzothiazol
core
design
compound
pgi
growth
cell
line
cn
cancer
pgi
studi
anticanc
activ
pyrazolin
moieti
posit
main
core
reveal
high
anticanc
potenti
mention
compound
scheme
sar
studi
confirm
depend
anticanc
activ
structur
fragment
isomer
thiazolidinon
possess
much
less
activ
level
thiazolidinoneisatin
conjug
good
exampl
polycycl
compound
high
anticanc
potenti
design
illustr
molecular
hybrid
approach
two
pharmacophor
combin
singl
molecul
instanc
posses
micromolar
activ
level
also
select
inhibit
leukemia
cell
line
structur
optim
led
increas
anticanc
activ
reflect
design
thiazolidinoneisatinpyrazol
hybrid
scheme
similar
isatinpyrazolin
conjug
without
thiazolidinon
core
nt
show
anticanc
activ
anoth
exampl
anticanc
isatinthiazolidinon
hybrid
compound
scheme
latter
result
structur
optim
sunitinib
sutent
tm
pfizer
inc
current
use
clinic
multitarget
tyrosin
kinas
inhibitor
antiangiogen
activ
approach
molecular
hybrid
use
design
bear
abromoacryloylamido
moieti
compound
known
anticanc
agent
scheme
apoptosi
relat
mechan
action
illustr
exampl
mention
compound
though
studi
proceed
till
thu
shown
act
differenti
interact
heat
shock
protein
kda
alloster
state
reactiv
function
therefor
treat
alloster
drug
one
exampl
hybrid
approach
anticanc
agent
design
combin
natur
compound
eg
oleanan
scaffold
thiazolidinon
core
scheme
among
oleananethiazolidinon
hybrid
carboxyimino
acid
methyl
ester
identifi
activ
substanc
pgi
ptgi
plc
nci
nih
protocol
low
toxic
moder
activ
level
vivo
hollow
fiber
assay
anoth
exampl
approach
bear
cholesterol
fragment
moreov
level
activ
select
antimitot
effect
depend
substitu
posit
thiazolidinon
core
maximum
effect
compound
exhibit
toward
hela
cancer
cell
line
promis
activ
molecul
base
combin
thiazolidinon
chromen
core
also
found
scheme
emphas
major
mention
compound
tendenc
toward
maximum
sensit
leukemia
lung
cancer
cell
line
shown
probabl
may
platform
effect
antileukem
agent
design
exampl
demonstr
cytotox
toward
leukem
cell
line
cem
induc
apoptosi
besid
modif
known
drug
exampl
assorafenib
fragment
report
scheme
wherea
lot
potenti
biotarget
new
anticanc
agent
design
known
present
almost
attempt
systemat
anticanc
agent
review
paper
exampl
three
aspect
pparsindepend
antitumor
activ
thiazolidinon
outlin
inhibit
function
ii
proteasom
degrad
target
protein
iii
transcript
repress
ar
degrad
though
latter
definit
repres
whole
spectrum
experiment
data
enough
design
novel
hitand
leadcompound
take
account
great
number
paper
tri
outlin
refer
biotarget
ligand
among
note
major
highaffin
ligand
belong
acid
imino
deriv
base
establish
role
ppar
cancer
inflamm
progress
consider
part
investig
dedic
studi
glitazon
relat
deriv
possibl
anticanc
agent
howev
analog
synthet
precursor
glitazon
contain
exocycl
doubl
bond
posit
possess
less
express
affin
ppar
agonist
pparg
antagonist
turn
repres
new
drug
class
hold
promis
broadli
applic
therapeut
approach
cancer
treatment
among
deriv
occupi
deserv
place
instanc
novel
benzoic
acid
deriv
scheme
potent
ppargspecif
antagonist
inhibit
prolifer
cell
line
concentrationdepend
manner
induc
cell
cycl
arrest
phase
interfer
cell
adhes
ppar
indep
anticanc
effect
troglitazon
mediat
mainli
via
repress
cyclin
breast
cancer
cell
facilit
proteasomefacilit
proteolysi
partial
deplet
intracellular
ca
store
lead
inhibit
translat
initi
troglitazon
structur
modif
led
identif
e
first
smallmolecul
agent
mediat
proteasom
degrad
cyclin
high
specif
exposur
caus
appreci
chang
express
level
seri
cyclin
cdkdepend
kinas
scheme
follow
structur
optim
screen
data
shown
equipot
troglitazon
ca
releas
activ
induct
phosphoryl
potent
inhibit
cancer
cell
prolifer
modif
allow
state
seri
thion
inhibit
cell
growth
low
micromolar
concentr
via
inhibit
translat
initi
involv
partial
deplet
intracellular
ca
store
strong
phosphoryl
structur
similar
benzylidenerhodanin
show
high
inhibit
protein
tyrosin
phosphatas
ic
mm
one
probabl
prognost
marker
metastat
cell
among
identifi
promis
select
inhibitor
enzym
dualspecif
phosphatas
group
e
phosphatas
jnkstimul
mention
compound
well
perspect
agent
explor
treatment
inflammatori
disord
scheme
scheme
relat
heterocycl
belong
new
class
small
molecul
e
inhibitor
necroptosi
regul
caspasindepend
pathway
cell
death
morpholog
featur
close
necrosi
may
use
faddchang
variant
treatment
jurkatt
cancer
cell
use
tnfa
hand
deriv
acid
nonhydroxam
inhibitor
tnfa
convert
enzym
allow
treat
promis
antiinflammatori
agent
give
prospect
establish
anticanc
potenti
given
class
compound
moreov
abil
hydantoincarboxyl
acid
especi
thiazol
fragment
inhibit
activ
ra
farnesyl
transferas
ftase
prove
ra
protein
play
essenti
role
process
cell
growth
differenti
need
post
translat
modif
includ
farnesyl
catalyz
ra
farnesyl
transferas
reason
rasftas
inhibitor
consid
potenti
anticanc
agent
structur
analog
given
substanc
ligand
neuroimmunophilin
protein
fkbp
acid
scheme
inhibitor
proteinprotein
interact
antiapoptot
protein
bax
famili
bind
appropri
receptor
domain
apart
direct
shown
hetyryl
scheme
identifi
potent
select
insulinlik
growth
receptor
inhibitor
growth
factor
receptor
tyrosin
kinas
famili
act
critic
mediat
cell
prolifer
surviv
although
highli
relat
insulin
receptor
play
differ
role
organ
develop
respons
normal
growth
develop
oppos
glucos
homeostasi
epidemiolog
studi
indic
overexpress
human
cancer
primarili
respons
tumor
genesi
signal
includ
activ
raf
pathway
inhibit
pathway
make
kinas
promis
target
cancer
therapi
moreov
seri
analog
pololik
kinas
key
regul
mitot
progress
cell
divis
eukaryot
act
concert
cyclindepend
kinas
e
cyclin
aurora
kinas
conduct
wide
rang
critic
cell
cycl
event
preclin
valid
cancer
target
smallmolecul
inhibitor
becom
attract
candid
anticanc
drug
develop
thiazolidinon
scheme
select
inhibit
human
ic
among
deriv
rhodanin
estrogenrel
receptora
erra
modul
identifi
use
prophylaxi
treatment
erra
associ
diseas
breast
cancer
follow
modif
high
select
inhibitor
seri
substitut
deriv
identifi
highli
activ
select
inhibitor
nanomolar
valu
ic
mm
serinethreonin
protein
kinas
frequent
overexpress
prostat
cancer
certain
form
leukemia
lymphoma
pim
phosphoryl
proapoptot
protein
bad
death
promot
lead
sequestr
protein
inhibit
apoptosi
alreadi
mention
imino
scheme
compris
one
investig
thiazolidinon
subtyp
compound
anticanc
activ
among
deriv
mmpt
identifi
hitcompound
abl
effect
inhibit
growth
lung
cancer
cell
line
time
influenc
normal
fibroblast
dose
respons
manner
studi
structureact
relationship
group
compound
reveal
structur
peculiar
nitrogen
atom
thiazolidin
core
unsubstitut
ii
dimethylaminobenzyliden
fragment
best
posit
iii
moieti
may
contain
substitu
differ
posit
aromat
ring
multidrugresist
phenotyp
crossresist
multipl
drug
divers
chemic
structur
one
welldocu
mdr
mechan
overexpress
encod
transmembran
atpdepend
drug
efflux
transport
pglycoprotein
pgp
respons
chemotherapi
pgp
prevent
intracellular
accumul
mani
cancer
drug
increas
thei
refflux
cancer
cell
well
hepat
renal
intestin
clearanc
pathway
attempt
coadminist
pgp
modul
inhibitor
increas
cellular
avail
block
action
pgp
met
limit
success
therefor
promis
approach
lie
design
discoveri
novel
compound
substrat
pgp
effect
drugresist
cancer
time
exhibit
minim
toxic
normal
cellular
function
mmpt
inhibit
growth
human
nonsmallcel
lung
cancer
colon
cancer
cell
drugsensit
drugresist
cell
line
independ
pglycoprotein
statu
besid
select
kill
drug
resist
cancer
cell
induc
apoptosi
among
deriv
effect
growth
inhibitor
cell
line
high
express
identifi
among
mention
deriv
effici
inhibitor
inhibitor
scheme
non
receptor
protein
tyrosin
phosphatas
mediat
cell
signal
growth
factor
cytokin
act
via
rasmap
kinas
pathway
discov
benzo
thiazol
deriv
turn
potent
thiazol
analog
thiazolidinon
oxazolidinon
deriv
establish
inhibitor
phosphatas
anticanc
agent
modifi
imidazolidin
deriv
new
cell
divis
cycl
kinas
inhibitor
design
z
benzylamino
one
select
lead
compound
scheme
n
disubstitut
diamin
bear
moieti
scheme
shown
nanomolar
inhibit
potenc
ic
nm
toward
tyrosin
phosphorylationregul
kinas
result
prompt
explor
symmetr
graft
posit
two
differ
platform
order
modul
potenti
biolog
activ
led
synthesi
unsymmetr
link
deriv
anticanc
effect
one
enerhodanin
prolifer
apoptosi
cancer
cell
identifi
well
influenc
metabol
alon
antioxid
immunomodul
action
context
interest
combin
anticanc
activ
antiinflammatori
effect
antioxid
andor
type
activ
compound
import
develop
classic
triad
oxid
stress
e
inflamm
e
cancer
addit
pharmacolog
profil
deriv
relat
free
radic
scaveng
activ
besid
note
prooxid
effect
thiazolidinon
anticanc
activ
frequent
found
paper
shown
deriv
increas
level
reactiv
oxygen
speci
ro
cell
moreov
ro
increas
block
ascorb
acid
addit
treatment
led
increas
level
ro
product
dna
strand
break
suggest
activ
apoptosi
induct
cell
death
leukem
cell
line
cem
plu
induc
block
phase
cell
exposur
select
compound
associ
product
ro
induct
autophagi
could
lead
cell
death
recent
observ
made
favour
altern
chemotherapeut
strategi
cancer
consist
increas
product
reactiv
oxygen
speci
moreov
gener
ro
could
activ
relat
factor
like
echassoci
protein
pathway
involv
protect
cell
oxid
stress
activ
pathway
lead
stabil
transloc
nucleic
db
ds
maf
protein
complex
bind
specif
dna
sequenc
defin
antioxid
respons
element
local
promot
target
gene
increas
transcript
gene
involv
reactiv
speciesmedi
respons
nadh
glutamylcysteyl
ligas
could
also
indic
indirect
impact
given
class
compound
proantioxid
balanc
ro
play
key
role
mitochondria
mediat
apoptosi
mitochondria
prime
sourc
ro
byproduct
aerob
respir
high
level
ro
mitochondria
result
free
radic
attack
membran
phospholipid
caus
mitochondri
membran
depolar
irrevers
step
associ
releas
mitochondri
factor
trigger
caspas
cascad
hand
immunoblot
analysi
show
significantli
elev
parkin
miro
express
level
acut
mptp
treat
mice
improv
mitochondri
membran
potenti
atp
synthesi
mpp
treat
cell
moreov
attenu
impair
mitochondri
transport
vesicl
releas
dysfunct
evok
mpp
cytotox
cultur
primari
mesencephal
neuron
taken
togeth
result
indic
improv
mitochondri
dysfunct
may
good
choic
delay
neurodegen
progress
commonli
associ
pakinson
diseas
well
cancer
among
propos
mechan
antitumor
effect
target
compound
apoptosi
induct
cell
cycl
arrest
differenti
extens
report
anticanc
effect
compound
also
achiev
block
cell
cycl
progress
phase
border
affect
phase
transit
revers
manner
induct
apoptosi
fac
fluorescenceactiv
cell
sort
analysi
acid
possess
strong
antiprolif
activ
human
leukemia
cell
show
remark
accumul
subploid
cell
sub
phase
follow
declin
phase
morerov
present
find
suggest
observ
growth
inhibit
could
due
apoptosi
relat
thiazolidinon
heterocycl
fragment
induc
cell
cycl
arrest
leukem
cell
phase
induc
cell
death
result
increas
level
phase
popul
therebi
affect
prolifer
caus
depolar
mitochondri
membran
potenti
similar
result
found
induc
cell
accumul
sub
phase
cell
cycl
furthermor
dissip
mitochondria
membran
potenti
observ
well
redox
chang
treat
cell
cell
line
treatment
cancer
cell
mention
mmpt
dbpt
led
timedepend
accumul
cell
arrest
phase
caus
prometaphaselik
mitot
g
em
arrest
atpcompetit
inhibitor
despit
divers
present
biotarget
note
thiazolidin
deriv
inductor
apoptosi
variou
cancer
cell
becom
frequent
apoptosisrel
mechan
associ
inhibit
function
howev
describ
anoth
feasibl
target
compound
affect
divers
apoptot
signal
pathway
name
induct
peroxisom
proliferatoractiv
receptorassoci
caspasedepend
mitochondriamedi
apoptosi
decreas
mitochondri
membran
potenti
one
import
mechan
mitochondri
mediat
apoptot
cell
death
exampl
compound
mkt
progress
antiinflammatori
agent
search
reach
via
high
affin
ligand
design
pharmacolog
screen
compound
unknown
molecular
mode
action
antiinflammatori
activ
associ
primarili
abil
inhibit
isoform
cyclooxygenas
cox
lipoxygenas
lox
success
repres
antiinflammatori
agent
base
darbufelon
e
scheme
attract
broad
attent
dual
inhibitor
cellular
prostaglandin
leukotrien
product
via
cyclooxygenas
activ
inhibit
includ
inhibit
prostaglandin
endoperoxid
chemic
structur
darbufelon
consid
leadcompound
novel
antiinflammatori
agent
design
till
optim
latter
applic
bioisoster
concept
allow
elabor
new
bioactiv
compound
scheme
signific
antiinflammatori
activ
well
antiedematogen
ulcerogen
activ
vivo
studi
relat
compound
allow
identifi
select
inhibitor
promis
antiinflammatori
agent
fewer
side
effect
obtain
data
sar
analysi
result
identifi
activ
compound
scheme
group
thiazolon
oxazolon
ditertbutylphenol
fragment
compound
inhibit
human
recombin
ic
mm
inhibit
activ
cell
line
ic
mm
compound
turn
inact
toward
concentr
mm
inhibit
thrombocyt
mm
among
scheme
found
potent
inhibitor
dehydrogenas
type
nad
depend
type
ii
nadp
prefer
cytosol
enzym
catalyz
oxid
prostaglandin
inhibit
enzym
relat
prostaglandin
action
lead
antiinflammatori
effect
instanc
reduc
hair
loss
structureact
analysi
indic
nmethyl
abolish
inhibitori
activ
also
establish
natur
moieti
link
anoth
linkag
play
import
role
inhibitori
activ
modif
led
new
relat
compound
identif
ic
mm
scheme
anoth
mechan
antiinflammatori
activ
inhibit
phosphodiesteras
phosphodiesteras
respons
hydrolysi
secondari
messang
camp
level
increas
inflamm
process
besid
phosphodiesteras
inhibitor
may
effect
agent
astma
obstruct
lung
diseas
treatment
establish
abil
includ
carboxyl
acid
inhibit
mention
enzym
moreov
unlik
rhodanin
deriv
carboxyl
deriv
select
inhibit
may
argument
studi
probabl
agent
parkinson
alzheim
diseas
antigen
effect
benzothiazol
isothiazol
moieti
scheme
human
chondrocyt
cultur
estim
studi
potent
inhibitor
metalloproteinas
mmp
given
experiment
model
reproduc
mechan
involv
osteoarthr
compound
ar
h
show
inhibit
activ
nanomolar
concentr
ic
moreov
among
antiinflammatori
seri
investig
atpcompetit
inhibitor
scheme
ic
mm
class
phosphoinositid
particular
becom
attract
drug
target
inflammatori
autoimmun
diseas
treatment
acid
nh
group
thiazolidinedion
core
hydroxyl
group
part
molecul
play
crucial
role
bind
contribut
class
select
besid
compound
inhibit
ic
nm
depend
pathway
insid
cell
murin
periton
model
produc
similar
decreas
leukocyt
infiltr
antiinflammatori
properti
scheme
relat
abil
block
product
action
degen
factor
induc
possess
antidegen
activ
human
chondrocyt
cultur
deriv
without
substitu
posit
well
analog
scheme
possess
antiinflammatori
activ
relat
type
activ
analges
activ
vitro
antioxid
activ
even
antimicrobi
structur
affin
pparg
agonist
silico
correl
studi
pparcompetit
bind
assay
indic
possibl
ppar
mediat
mode
antiinflanmatori
action
similarli
scheme
exhibit
antiinflammatori
effect
carrageenaninduc
paw
edema
model
caus
reduct
level
togeth
insignific
inhibit
compar
celecoxib
note
thiazolidinon
possess
much
less
express
effect
inact
appli
procedur
virtual
highthroughput
screen
studi
led
identif
compound
scheme
antiinflammatori
activ
vivo
cyclooxygenas
lipoxygenas
inhibit
assay
well
antiinflammatori
assay
compound
turn
promis
agent
studi
field
row
hybrid
scheme
scheme
base
indometacin
roziglitazon
darbufelon
molecul
design
molecul
posses
vivo
antiinflammatori
activ
air
pouch
periton
model
carrageenan
induc
paw
edema
model
inhibit
number
relat
scheme
screen
antiinflammatori
effect
compound
exhibit
signific
level
antiinflammatori
activ
assay
induc
edema
mous
paw
acid
aryliden
aryl
amid
scheme
also
shown
signific
activ
carrageenan
test
applic
polypharmacolog
approach
advanc
pathophysiolog
role
variou
biotarget
result
great
interest
search
new
antiinflanmatori
agent
exampl
establish
aldos
reductas
ar
critic
involv
inflammatori
process
normoglycem
diabet
condit
enzym
overexpress
variou
oxid
condit
interven
multipl
signal
pathway
lead
inflamm
tissu
degener
accordingli
ascertain
ar
inhibit
prevent
multipl
inflammatori
pathway
therefor
new
effect
safer
ar
inhibitor
design
antidiabet
see
also
antinflammatori
agent
peripher
blood
mononuclear
cell
exert
nfkb
inhibit
relat
compound
also
antioxid
activ
xanthin
oxidas
inhibitori
potenc
among
deriv
first
small
molecul
abl
inhibit
hiv
replic
target
cellular
enzym
e
rna
helicas
identifi
precis
combin
function
group
rhodanin
scaffold
shown
respons
inhibitori
activ
select
hit
compound
scheme
salicyl
acid
contain
compound
potent
integras
inhibitor
integras
catalyz
integr
provir
dna
host
genom
essenti
step
viral
replic
among
sever
compound
retriev
databas
smallmolecul
compound
scheme
inhibit
strand
transfer
activ
integras
similar
ic
valu
mm
replac
either
rhodanin
salicyl
acid
fragment
found
reduc
integras
inhibitori
potenc
acid
amid
bicycl
analog
scheme
repres
new
class
inhibitor
integras
antivir
agent
identifi
silico
studi
model
integras
inhibitor
well
vitro
investig
employ
hcv
protein
target
directli
act
antivir
agent
identifi
collect
describ
specif
target
antivir
therapi
hcv
statc
approach
small
molecul
inhibitor
search
hepat
c
viru
treatment
mainli
focus
upon
inhibit
essenti
viral
target
proteas
analog
hiv
proteas
polymeras
helicas
literatur
survey
hcv
polymeras
inhibitor
clearli
indic
could
inhibit
enzym
might
promis
candid
develop
novel
antivir
agent
hcv
screen
inhous
librari
allow
identifi
deriv
scheme
hitcompound
ic
identifi
investig
led
nsubstitut
aryl
alkylidenerhodanin
synthesi
inhibit
hcv
proteas
also
good
inhibitor
serin
proteas
chymotrypsin
plasmin
select
compound
scheme
bulkier
fragment
bear
hydrophob
function
group
well
simpl
analog
scheme
increas
ten
fold
toward
hcv
proteas
respect
group
rhodanin
scheme
initi
structur
new
inhibitor
hcv
polymeras
design
mainli
case
inhibit
lower
ic
valu
rang
mm
moreov
author
argu
contribut
ar
yliden
group
stabil
bind
mode
activ
site
investig
led
new
leadcompound
identif
thu
deriv
acid
activ
toward
hcv
inhibit
viru
proteas
addit
establish
abil
deriv
compound
class
inhibit
human
serin
proteas
sar
analysi
show
substitut
aryliden
moieti
carboxi
methyliden
fragment
led
insignific
loss
activ
scheme
base
previou
data
seri
thiazolidinon
scheme
synthes
antivir
activ
influenza
virus
type
b
corona
viru
sar
tacarib
viru
dengu
viru
rift
valley
fever
viru
respiratori
syncyti
viru
vaccinia
viru
venezuelan
equin
enceph
viru
test
vitro
molecular
hybrid
method
allow
obtain
thiazolidinoneepeptid
hybrid
scheme
inhibit
dengu
viru
proteas
moreov
determin
thiazolidinon
core
rhodanin
peptid
accomplish
rel
rigid
aryliden
moieti
use
parasubstitut
violat
antioxid
defenc
system
balanc
proantioxid
describ
major
patholog
includ
mention
therefor
lot
paper
dedic
studi
antioxid
activ
articl
describ
investig
antirad
properti
model
system
evalu
effici
free
radic
scaveng
eg
scaveng
activ
dpph
combin
studi
type
activ
particular
antitumor
antiinflammatori
see
data
concern
class
bear
differ
type
yliden
fragment
deriv
scheme
possess
antirad
activ
includ
abil
inhibit
superoxid
anion
format
known
antioxid
activ
increas
addit
carboxyl
group
introduc
substitu
posit
heterocycl
core
substitut
unsubstitut
deriv
simpl
rhodanin
antioxid
activ
variou
ldl
oxid
model
tbar
assay
conjug
dien
format
rem
oxldl
fragment
apo
sdspage
radic
dpph
scaveng
activ
macrophagemedi
ldl
oxid
show
note
branch
aliphat
fragment
preval
spatiallyscreen
phenol
larg
contribut
imit
known
agent
eg
bht
probucol
antioxid
properti
seri
deriv
scheme
report
two
differ
vitro
assay
superoxid
anion
radic
format
dpph
radic
scaveng
activ
presenc
benzylsulfanyl
group
second
posit
thiazol
ring
play
signific
role
increas
superoxid
anion
scaveng
activ
correl
observ
result
superoxid
radic
dpph
radic
scaveng
capac
simpl
thiazolidinedion
deriv
z
scheme
play
crucial
role
uvinduc
melanogenesi
known
relat
induct
tyrosinas
enzym
compound
inhibit
nitroprussideinduc
gener
dosedepend
suppress
tyrosinas
activ
melanin
synthesi
melanoma
cell
seri
scheme
analog
inhibit
ar
possess
dual
activ
antidiabet
antioxid
agent
treatment
diabet
complic
result
indic
latter
possess
excel
antioxid
properti
inhibit
product
tbar
test
compound
effect
hydroxyl
radicaldepend
lipoperoxid
induc
rat
brain
homogen
oxid
system
fe
ascorb
acid
observ
presenc
electron
releas
substitu
distal
phenyl
ring
differenti
antioxid
activ
compound
detail
mechan
antioxid
effect
compound
class
still
unclear
explain
abil
inhibit
superoxid
anion
ro
product
also
influenc
part
proantioxid
system
chang
classic
approach
evalu
proantioxid
emerg
new
approach
interpret
antioxid
effect
studi
relat
free
radic
scaveng
mechan
antioxid
attent
paid
studi
molecular
mechan
stimul
antioxid
defenc
system
includ
possibl
substanc
prooxid
impact
subsequ
stimul
antioxid
defenc
system
see
e
anticanc
agent
larg
number
biotarget
involv
differ
patholog
lot
data
efficaci
differ
experiment
model
instanc
molecular
dock
studi
indic
moieti
like
candid
select
monoamin
oxidaseb
hypothesi
confirm
identif
two
leadcompound
scheme
ic
mm
involv
varieti
cellular
process
consid
promis
target
treatment
variou
cardiovascular
diseas
neurodegen
diseas
sever
liver
kidney
diseas
etc
time
sever
kinas
exampl
cyclindepend
kinas
famili
attract
target
design
high
affin
inhibitor
base
scheme
identifi
virtual
screen
repres
novel
glycogen
synthas
inhibitor
activ
confirm
experiment
emerg
key
therapeut
target
diabet
melitu
alzheim
diseas
cancer
chronic
inflamm
experiment
evid
inhibitor
activ
neg
regul
nfkb
activ
apoptosi
enhanc
trailinduc
cell
death
phenyl
identifi
potent
select
blocker
cystic
fibrosi
transmembran
conduct
regul
cftr
clchannel
moreov
act
differ
known
blocker
cftr
channel
rather
block
channel
pore
affect
mechan
channel
gate
possibl
bind
nucleotid
bind
domain
cftr
member
atpbind
cassett
transport
superfamili
epitheli
chlorid
channel
play
critic
role
fluid
absorpt
secret
defect
cftr
function
caus
cystic
fibrosi
common
lethal
genet
diseas
caucasian
produc
sever
lung
diseas
pancreat
insuffici
neonat
intestin
obstruct
infertil
hyperfunct
cftr
chlorid
channel
usual
result
bacteri
enterotoxin
constitut
benzylidenerhodanin
deriv
show
good
inhibitori
activ
recombin
human
phosphatas
regener
liver
represent
protein
tyrosin
phosphatas
compound
scheme
activ
vitro
seri
show
abil
reduc
invas
tumor
follow
virtual
screen
potent
serotonin
nacetyltransferas
member
superfamili
catalyz
penultim
step
biosynthesi
melatonin
inhibitor
class
acid
scheme
identifi
exhibit
low
micromolar
competit
inhibit
acetylcoa
prove
effect
block
melatonin
product
pineal
cell
deriv
scheme
exhibit
antidegen
activ
could
block
multipl
cartilag
destruct
osteoarthrit
process
reduc
releas
restor
normal
level
glycosaminoglycan
chondrocyt
treat
beta
possess
inhibit
activ
mmp
larg
famili
calcium
depend
zinc
contain
endopeptidas
respons
tissu
remodel
extracellular
matrix
degrad
compound
found
endow
interest
activ
level
model
acut
inflamm
carrageenaninduc
paw
pleurisi
edema
rat
inhibitor
cox
isoform
deriv
propos
treatment
nonalcohol
fatti
liver
diseas
compound
scheme
found
upregul
adiponectin
protein
express
regul
secret
leptin
protein
adipocyt
respect
concentr
mm
z
methyl
benzoic
acid
scheme
describ
potent
full
agonist
human
class
orphan
receptor
describ
potenti
novel
drug
target
design
compound
therapeut
applic
number
diseas
includ
inflamm
metabol
disord
nocicept
cardiovascular
diseas
olefin
thiazolidinedion
scheme
found
potent
select
receptor
ec
mm
ia
agonist
vs
vs
activ
primari
hit
analog
agonist
potenti
drug
treatment
obes
type
ii
diabet
frequent
urin
relat
diseas
relat
thiazolidinon
cyanamid
hydroxylamin
scheme
substitu
gener
potent
toward
receptor
howev
select
receptor
relat
benzimidazolon
scheme
display
good
agonist
select
profil
describ
inhibitor
member
adamt
adisint
grin
metalloproteas
thrombospondin
motif
famili
zinc
metalloproteas
inhibit
therefor
protect
cartilag
damag
provid
first
potenti
therapi
halt
andor
revers
progress
osteoarthr
compound
least
activ
analog
result
virtual
screen
scheme
found
potent
canabinoid
receptor
type
antagonist
promis
bind
affin
ic
nm
also
display
good
pharmacokinet
profil
rat
well
human
plasma
novel
class
receptor
agonist
base
scaffold
act
scheme
found
activ
compound
vitro
vivo
assay
select
agonist
receptor
therapeut
interest
abil
halt
exit
lymphocyt
lymph
node
interrupt
lymphocyt
migrat
promis
new
immunomodulatori
therapeut
principl
varieti
autoimmun
diseas
new
class
identifi
new
inhibitor
chondroprotect
agent
mode
action
also
relat
decreas
nfkb
level
optovin
methyliden
scheme
detect
small
molecul
enabl
repeat
photo
activ
motor
behavior
wild
type
anim
optovin
act
lightsensit
ligand
anion
channel
involv
detect
pain
sensori
stimuli
activ
human
via
structuredepend
photochem
reaction
redoxsensit
cystein
residu
optovin
treatment
enabl
control
motor
activ
paralyz
extrem
local
illumin
studi
identifi
lightbas
strategi
control
endogen
mention
optovin
rare
exampl
eisom
diseas
summar
deservedli
consid
privileg
heterocycl
wide
spectrum
biolog
activ
assign
pain
due
possibl
michael
acceptor
function
unambigu
requir
studi
therefor
compound
reject
per
se
two
main
direct
present
literatur
data
screen
compound
activ
without
confirm
mode
action
ii
search
highli
activ
select
ligand
socal
valid
biotarget
definit
nt
negat
search
antitumor
hypoglycem
antimicrobi
antivir
antiinflammatori
agent
main
field
studi
moreov
work
dedic
investig
antitumor
potenti
compound
despit
seri
establish
biotarget
detail
mode
anticanc
effect
undoubtedli
depend
structur
particular
deriv
need
studi
howev
major
apoptosisdepend
well
ro
mediat
mode
action
establish
main
direct
activ
optim
devid
follow
complic
fragment
bulkysubstitu
unsubstitut
posit
prefer
ii
introduct
substitu
posit
especi
fragment
bear
carboxyl
group
deriv
iii
annul
complex
fuse
heterocycl
system
iv
combin
pharmacolog
attract
fragment
within
hybrid
pharmocophor
approach
follow
divers
chemic
pharmacolog
properti
treat
build
block
synthesi
variou
deriv
step
socal
privileg
substructurebas
divers
orient
synthesi
strategi
prove
fruit
tool
rapidli
discov
biolog
activ
leadcompound
moreov
recent
follow
thesi
put
forward
compound
base
mainli
annel
system
eg
thiopyrano
thiazol
possess
similar
pharmacolog
profil
consid
cyclic
biomimet
synthet
precursor
regardless
type
thiazolidinon
core
tri
outlin
reaction
common
particular
involv
exocycl
doubl
bond
reduct
exocycl
doubl
bond
form
planar
conjug
system
could
rel
easi
reduc
lead
format
correspond
unconjug
structur
scheme
challeng
problem
type
nonconjug
system
basic
studi
exampl
glitazon
see
rel
simplic
enol
physiolog
condit
make
stereochemistri
difficult
maintain
posit
lithium
h
epdc
dioxan
nahg
thfh
mg
methanol
zinc
acet
acid
etc
use
reduc
agent
reaction
mainli
studi
phase
glytazon
synthesi
appropri
reaction
condit
allow
select
reduc
doubl
bond
leav
intact
molecular
fragment
eg
case
acid
reduct
complex
scheme
format
fuse
heterocycl
system
describ
treatment
pyrazoleethiazolidinon
deriv
sodium
hydrid
n
ndimethylformamid
caus
dimeris
reaction
give
correspond
spiro
compound
exocycl
doubl
bond
good
olefin
varieti
addit
reaction
eg
michael
addit
reaction
condit
eg
microwav
irradi
confirm
doubt
realiz
reaction
physiolog
condit
see
consid
michael
acceptor
michael
addit
follow
knoevenagel
condens
phase
domino
tandem
multicompon
reaction
reaction
aromat
aldehyd
ndithiocarbamin
involv
consecut
knoevenagel
condens
michael
addit
scheme
reaction
stereoselect
carri
dri
condit
microwav
irradi
dithioest
intermolecular
cycliz
iodin
montmorillonit
li
clay
montmorillonit
clay
action
gave
appropri
heterocycl
util
c
synthon
known
cyclocondens
reaction
led
bisthiazolidinon
format
latter
eas
reduc
ad
zinc
acet
acid
bisthiazolidinon
readili
oxid
start
presenc
catalit
ammount
triethylamin
scheme
similarli
scheme
synthes
base
reaction
oaminothiophenol
follow
dehydrogen
appropri
presenc
triethylamin
dmf
threecompon
onepot
procedur
synthesi
pyranannul
thiazol
involv
situ
gener
azlacton
format
pyranothiazol
best
explain
michael
addit
azlacton
success
appli
cascad
reaction
construct
spiro
rhodanin
scheme
multipl
consecut
chiral
center
catalyz
simpl
diamin
effici
nbocltryptophan
provid
product
high
stereoselect
use
compon
michael
addit
hydroxylamin
hydrochlorid
yield
novel
spiro
cyclohexaneisoxazolothiazol
deriv
addit
bunsatur
keton
use
synthesi
correspond
oxiranyl
deriv
treatment
hydrogen
peroxid
presenc
sodium
hydroxid
also
start
thiazolidinon
treat
ethylcyanoacet
medium
acet
acid
presenc
sodium
acet
reflux
afford
correspond
pyranothiazolecarbonitril
deriv
scheme
similar
heterocycl
base
start
compound
describ
reaction
difunct
nucleophil
thiourea
hydrazin
hydrat
deriv
malononitril
ethylcyanoacet
yield
thiazolo
bromin
doubl
bond
effici
approach
synthesi
compound
high
antimicrobi
activ
scheme
deriv
react
grignard
reagent
via
addit
exocycl
doubl
bond
afford
scheme
reaction
rare
found
current
literatur
data
thiazolidinon
deriv
conjug
carbonyl
group
react
difunct
nucleophil
phenylhydrazin
ethanol
presenc
sodium
acet
give
core
stabl
alkali
medium
featur
often
explor
cycliz
reaction
attract
start
reagent
synthesi
acid
alkalin
hydrolysi
lead
mention
acid
format
scheme
possibl
acid
util
thiolic
agent
onepot
threecompon
reaction
synthesi
propos
base
retrosynthet
approach
contain
substitu
ortho
posit
aryliden
fragment
special
interest
effici
approach
synthesi
isothiocoumarin
deriv
relat
compound
structur
depend
natur
substitu
orthoposit
aryl
heter
yliden
fragment
base
mention
scheme
base
hydrolysi
rhodanin
twostep
reaction
occur
intermedi
hydrolysi
undergo
heterocycl
format
acid
ketocinchonin
acid
acid
etc
action
hydrazin
thiosemicarbazon
yield
pyrazolin
deriv
scheme
synthesi
similar
pyrazol
deriv
also
describ
start
scheme
simpl
synthesi
develop
base
reaction
thiosemicarbazid
alkalin
medium
base
mention
approach
optim
introduct
bulki
heterocycl
fragment
molecul
via
recycl
yliden
fragment
contain
highli
reactiv
group
mainli
ortho
posit
propos
scheme
though
present
protocol
persuas
take
consider
transform
instabl
core
basic
medium
see
thionat
one
effect
approach
modif
order
synthezis
pyrazolo
thiazol
system
condens
hydrazin
studi
thiazolidinethion
condens
hydrazin
deriv
dmf
yield
singl
product
regioselect
synthesi
thiazol
scheme
effici
heterodien
heterodielseald
cycloaddit
one
power
method
construct
fuse
heterocycl
bear
thiazolidinon
fragment
scheme
thiopyrano
thiazol
usual
synthes
via
cycloaddit
heterodielsald
reaction
contain
group
structur
activ
heterodien
thiopyrano
thiazol
special
interest
cyclic
isoster
mimic
synthet
precursor
without
michael
accept
function
see
maleic
acid
deriv
acryl
acid
deriv
acrylonitril
bnitrostyren
norbornen
acid
deriv
cynnam
acid
propiol
acid
aroylpyruv
acid
etc
studi
heterodien
condens
dienophil
cycloaddit
highli
regioand
srereoselect
form
product
accord
frontier
orbit
theori
interest
result
describ
substitu
orthoposit
phenyl
ring
util
type
reaction
reaction
latter
croton
acid
anhydrid
cynnam
acid
acryl
acid
ester
involv
tandem
heterodielseald
acyl
process
afford
tetracycl
fuse
heterocycl
chromeno
thiopyrano
thiazol
scheme
similar
rhodanin
deriv
react
malononitril
give
fuse
chromeno
pyrano
due
instabl
rhodanin
basic
medium
high
temperatur
yield
cyclocondens
product
low
scheme
often
intermedi
mention
tandem
reaction
involv
heterodielseald
reaction
scheme
rare
report
util
rhodanin
deriv
heterodielsald
reaction
exampl
reaction
norbornen
fuse
tiopyranothiazol
deriv
form
scheme
reaction
arylidenerhodanin
maleic
anhydrid
nphenylmaleimid
dmad
perform
mw
irradi
led
pyrano
thiazol
format
besid
deriv
type
describ
instanc
start
materi
polycycl
system
format
scheme
final
product
format
accompani
elimin
alcohol
molecul
oxid
case
rhodanin
deriv
success
use
dienophil
react
variou
asymmetr
dielsald
reaction
lead
construct
structur
complex
compound
contain
rhodanin
motif
scheme
reaction
also
diastereoand
enantioselect
threecompon
cycloaddit
reaction
isatin
sarcosin
ethanol
ultrasound
irradi
effici
protocol
synthesi
dispiropyrrolidin
deriv
scheme
analougu
two
step
condens
reaction
afford
similar
complex
spiro
deriv
describ
base
one
contain
fix
fragment
structur
scheme
mention
compound
form
racem
mixtur
two
enantiom
result
addit
azomethin
ylide
reaction
proceed
diastereoselect
e
follow
nmr
data
michael
reaction
acet
acid
afford
fuse
heterocycl
system
contain
anazolon
moieti
reaction
involv
intramolecular
cycliz
appropri
intermedi
oxid
aromat
scheme
class
illustr
exampl
socal
privileg
heterocycl
modern
medicin
chemistri
possess
wide
rang
pharmacolog
activ
major
achiev
studi
relat
antitumor
hypoclycem
antivir
antimicrobi
activ
despit
deriv
assign
panassay
interfer
compound
possibl
low
affin
sever
biotarget
suffici
select
properti
michael
acceptor
vivo
studi
precis
object
affin
toward
differ
target
may
consid
advantag
basi
modif
aim
increas
select
anoth
